RxDoctor Payments Data

Frank Kohler, DO

Endocrinology, Diabetes & Metabolism · Daytona Beach, FLNPI 1356432090

Payments from drug & device makers

$1,085in general payments, 2019–2025

Across 74 payments — averaging $14.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Insulet Corporation$204
  • Medtronic$181
  • Novo Nordisk$165
  • Sanofi-aventis U.S. LLC$92
  • Abbott$68
  • AstraZeneca$67
  • plus $307 from 12 others

What the payments were for

  • Food & beverage$1,085100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,085 in reported general payments places this provider in the 30th percentile of 586 endocrinology, diabetes & metabolism providers in Florida.

See all endocrinology, diabetes & metabolism providers in Florida

Medicare billing

Part B allowed, 2024
$293,701
Medicare patients
927
Services billed
3,025

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide237$365,469
MounjaroTirzepatide161$211,104
JardianceEmpagliflozin148$207,713
TrulicityDulaglutide100$151,218
RybelsusSemaglutide67$126,760
Tresiba Flextouch U-200Insulin Degludec98$120,108
Tresiba Flextouch U-100Insulin Degludec151$119,761
FarxigaDapagliflozin Propanediol89$96,411
Fiasp FlextouchInsulin Aspart (Niacinamide)85$86,426
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/761$74,112
Humalog Kwikpen U-200Insulin Lispro15$66,907
Novolog FlexpenInsulin Aspart154$45,913
Lantus SolostarInsulin Glargine,hum.Rec.Anlog256$44,243
NovologInsulin Aspart126$38,324
ProliaDenosumab19$32,712

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus, Novolog, Tresiba, Novolog Mix 70-30$165$564,344462 claims
Lilly USA, LLCMounjaro, Trulicity, Humalog, Humalog Mix 75-25$55$380,135308 claims
Boehringer IngelheimJardiance, Synjardy$12$227,551167 claims
AstraZenecaFarxiga$67$96,41189 claims
AmgenProlia$16$32,71219 claims
Sanofi-aventis U.S. LLCLantus, Soliqua 100-33$92$23,48777 claims
Johnson & JohnsonInvokana$13$15,98214 claims
AbbVieSynthroid$24$13,775135 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$15$7,082546 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 586 endocrinology, diabetes & metabolism providers in Florida.

Other endocrinology, diabetes & metabolism in Daytona Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →